Cargando…

Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study

OBJECTIVE: To investigate limiting factors of American College of Rheumatology (ACR)/EULAR Boolean remission in rheumatoid arthritis (RA), and compare patients who fulfil the criteria to patients who only partly fulfil the criteria, with respect to imaging inflammation and biologic disease modifying...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paulshus Sundlisæter, Nina, Sundin, Ulf, Aga, Anna-Birgitte, Sexton, Joseph, Hammer, Hilde Berner, Uhlig, Till, Kvien, Tore K, Haavardsholm, Espen A, Lillegraven, Siri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804675/ https://www.ncbi.nlm.nih.gov/pubmed/35091463 http://dx.doi.org/10.1136/rmdopen-2021-002013

Ejemplares similares

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial
por: Nordberg, Lena Bugge, et al.
Publicado: (2018)

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy
por: Sundin, Ulf, et al.
Publicado: (2021)

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
por: Holten, Karen, et al.
Publicado: (2022)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Comparative analyses of responsiveness between the Rheumatoid Arthritis Impact of Disease score, other patient-reported outcomes and disease activity measures: secondary analyses from the ARCTIC study
por: Holten, Karen, et al.
Publicado: (2018)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project
por: van Beers-Tas, Marian H, et al.
Publicado: (2018)

Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre
por: Reuter, Katja, et al.
Publicado: (2022)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022)

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis
por: Kolan, Shrikant S., et al.
Publicado: (2022)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
por: van Vollenhoven, Ronald F., et al.
Publicado: (2018)

Effects of exercise and physical activity promotion: meta-analysis informing the 2018 EULAR recommendations for physical activity in people with rheumatoid arthritis, spondyloarthritis and hip/knee osteoarthritis
por: Rausch Osthoff, Anne-Kathrin, et al.
Publicado: (2018)

Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data
por: Alemao, Evo, et al.
Publicado: (2016)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis
por: Roodenrijs, Nadia M T, et al.
Publicado: (2021)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis
por: Mankia, Kulveer, et al.
Publicado: (2021)

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study
por: Saraux, Alain, et al.
Publicado: (2020)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
por: Kvien, Tore K, et al.
Publicado: (2020)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs
por: Pukšić, Silva, et al.
Publicado: (2018)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
por: Saevarsdottir, Saedis, et al.
Publicado: (2022)

One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study
por: Uhlig, Till, et al.
Publicado: (2022)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit
por: Semb, Anne Grete, et al.
Publicado: (2021)

Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis
por: Horton, Sarah C, et al.
Publicado: (2017)

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study
por: Uhlig, Till, et al.
Publicado: (2021)

Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
por: Genovese, M C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2delq3mt8ohiprr380d4abtc6r